News | May 16, 2025
Sanofi India posts 27% growth in operating profits in Q1 2025
Standalone profit from operations for the quarter were Rs. 162 crores
Standalone profit from operations for the quarter were Rs. 162 crores
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
EBITDA before special items decreases to €4.08 billion (7.4%)
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Subscribe To Our Newsletter & Stay Updated
